CAS: 2169919-21-3
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | SNDX-5613 REF: TM-T12943CAS: 2169919-21-3 | 99.12% | 72.00 €~1,049.00 € | Tue 07 Jan 25 |
 | Revumenib REF: 4Z-R-171001CAS: 2169919-21-3 | - - - | To inquire | Mon 13 Jan 25 |
 | SNDX-5613 REF: 3D-ULD91921CAS: 2169919-21-3 | Min. 95% | To inquire | Tue 18 Feb 25 |
SNDX-5613
CAS:2169919-21-3
Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction.Cost-effective and quality-assured.
Formula:
C32H47FN6O4S
Purity:
99.12%
Color and Shape:
Solid
Molecular weight:
630.82
Ref: TM-T12943
| 1mg | 72.00 € | ||
| 2mg | 95.00 € | ||
| 5mg | 157.00 € | ||
| 10mg | 269.00 € | ||
| 25mg | 531.00 € | ||
| 50mg | 761.00 € | ||
| 100mg | 1,049.00 € | ||
| 1mL*10mM (DMSO) | 217.00 € |
Estimated delivery in United States, on Tuesday 7 Jan 2025
Ref: 4Z-R-171001
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Estimated delivery in United States, on Monday 13 Jan 2025
SNDX-5613
CAS:2169919-21-3
Revumenib, also known as SNDX-5613, is a potent and selective inhibitor of the interaction between …
Formula:
C32H47FN6O4S
Purity:
Min. 95%
Molecular weight:
630.8 g/mol
Ref: 3D-ULD91921
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Estimated delivery in United States, on Tuesday 18 Feb 2025
